Vaccitech well funded through 2024/25 as it progresses its novel immunotherapeutics and vaccines

Vaccitech (NASDAQ:VACC) CEO Bill Enright joined Proactive’s Stephen Gunnion with details of the latest clinical developments at the company following a production second quarter, which saw it ending June with cash and cash equivalents of $192.3 million.

Enright highlighted interim data from the clinical-stage biopharmaceutical firm’s ongoing Phase 1b/2a clinical trial of VTP-300 in patients with chronic hepatitis B.

Vaccitech also recognized further royalty and milestone payments related to the sales of Vaxzevria, AstraZeneca’s COVID-19 vaccine, which he said have contributed significant non-dilutive capital to support the company’s clinical and preclinical programs going forward.

“We have cash at least through the end of 2024 if we receive no additional royalty payments,” Enright told Proactive. “We’ll most likely be able to get well into 2025 with our current cash position.”